New Products
Onivyde (nanoliposomal irinotecan as sucrosofate) is a topoisomerase inhibitor formulated into a liposomal dispersion for intravenous use. Onivyde has been shown to extend circulation of irinotecan and prolong the duration of active therapy at the site of tumour cells to inhibit tumour growth. Onivyde is not equivalent to nonliposomal irinotecan formulations and should not be interchanged. Onivyde is indicated for treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and folinic acid (leucovorin) in adults who have been previously treated with gemcitabine based therapy. Onivyde is available as one 10 mL vial containing irinotecan sucrosofate equivalent to 43 mg irinotecan (or 50 mg irinotecan hydrochloride trihydrate).
Ristempa (pegfilgrastim (rbe)) is a long-acting form of recombinant human granulocyte colony stimulating factor (G-CSF). Ristempa is composed of filgrastim (recombinant methionyl human G-CSF, Neupogen) with a 20,000 dalton polyethylene glycol (PEG) molecule covalently bound to the N-terminal methionine residue. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo compared to filgrastim. Ristempa is indicated for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and so reduce the incidence of infection, as manifested by febrile neutropenia. Ristempa is contraindicated with known hypersensitivity to Escherichia coli derived proteins, or filgrastim. Ristempa is available as one ready to use prefilled syringe containing 6 mg of pegfilgrastim in 0.6 mL (10 mg/mL).